Potassium Phosphates In 0.9% Sodium Chloride is a drug owned by Fresenius Kabi Usa Llc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 12, 2041. Details of Potassium Phosphates In 0.9% Sodium Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11925661 | Ready-to-use potassium phosphates in sodium chloride solutions |
Oct, 2041
(16 years from now) | Active |
| US11813291 | Ready-to-use potassium phosphates in sodium chloride solutions |
Oct, 2041
(16 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Potassium Phosphates In 0.9% Sodium Chloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Potassium Phosphates In 0.9% Sodium Chloride's family patents as well as insights into ongoing legal events on those patents.
Potassium Phosphates In 0.9% Sodium Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Potassium Phosphates In 0.9% Sodium Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 12, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Potassium Phosphates In 0.9% Sodium Chloride Generic API suppliers:
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic is the generic name for the brand Potassium Phosphates In 0.9% Sodium Chloride. 4 different companies have already filed for the generic of Potassium Phosphates In 0.9% Sodium Chloride, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Potassium Phosphates In 0.9% Sodium Chloride's generic
Alternative Brands for Potassium Phosphates In 0.9% Sodium Chloride
There are several other brand drugs using the same active ingredient (Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic) as Potassium Phosphates In 0.9% Sodium Chloride. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Cmp Dev Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic, Potassium Phosphates In 0.9% Sodium Chloride's active ingredient. Check the complete list of approved generic manufacturers for Potassium Phosphates In 0.9% Sodium Chloride
About Potassium Phosphates In 0.9% Sodium Chloride
Potassium Phosphates In 0.9% Sodium Chloride is a drug owned by Fresenius Kabi Usa Llc. Potassium Phosphates In 0.9% Sodium Chloride uses Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic as an active ingredient. Potassium Phosphates In 0.9% Sodium Chloride was launched by Fresenius Kabi Usa in 2019.
Approval Date:
Potassium Phosphates In 0.9% Sodium Chloride was approved by FDA for market use on 26 November, 2019.
Active Ingredient:
Potassium Phosphates In 0.9% Sodium Chloride uses Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic as the active ingredient. Check out other Drugs and Companies using Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic ingredient
Dosage:
Potassium Phosphates In 0.9% Sodium Chloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.18GM/100ML(11.8MG/ML); 1.12GM/100ML(11.2MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 1.18GM/250ML(4.72MG/ML); 1.12GM/250ML(4.48MG/ML) | SOLUTION | Prescription | INTRAVENOUS |